BRD4 and neuroblastoma: We also determined the effect of manipulation of the PTEN/PI3K/AKT signaling pathway on growth of neuroblastoma xenografts in vivo and in vitro by treatment with an RGD-targeted dual PI3K/BRD4 inhibitor, with anti-tumor and anti-angiogenic activity, SF1126.